iBio announces that it has entered into a collaboration agreement with AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio‘s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise. As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four targets for the treatment of cardiometabolic disease. As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a novel lead program focused on targeting the transforming growth factor beta superfamily for the treatment of muscle wasting and obesity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBIO:
- iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
- iBio Announces $15.0 Million Private Placement
- Biotech Alert: Searches spiking for these stocks today
- Ibio Inc Advances Portfolio with Strategic Asset Sale
- iBio to sell preclinical PD-1 agonist antibody program to Otsuka